AAAAAA

   
Results: 1-10 |
Results: 10
EGF-LIKE REPEATS OF VERSICAN INHIBIT CELL-DIFFERENTIATION AND PROMOTEPROLIFERATION, DELETION OF WHICH PLAYS A DOMINANT-NEGATIVE EFFECT ON GLIOMA GROWTH
Authors: YANG BB ZHANG Y LIU C YANG BL ANG LC KIANI C HU W
Citation: Bb. Yang et al., EGF-LIKE REPEATS OF VERSICAN INHIBIT CELL-DIFFERENTIATION AND PROMOTEPROLIFERATION, DELETION OF WHICH PLAYS A DOMINANT-NEGATIVE EFFECT ON GLIOMA GROWTH, Molecular biology of the cell, 9, 1998, pp. 320-320
EXPRESSION OF THE G1 DOMAIN OF AGGRECAN INTERFERES WITH CHONDROCYTE ATTACHMENT AND ADHESION
Authors: CAO L ZHANG Y YANG BB
Citation: L. Cao et al., EXPRESSION OF THE G1 DOMAIN OF AGGRECAN INTERFERES WITH CHONDROCYTE ATTACHMENT AND ADHESION, Matrix biology, 17(5), 1998, pp. 379-392
AGGRECAN AND LINK PROTEIN AFFECT CELL-ADHESION TO CULTURE PLATES AND TO TYPE-II COLLAGEN
Authors: YANG BB ZHANG Y CAO L YANG BL
Citation: Bb. Yang et al., AGGRECAN AND LINK PROTEIN AFFECT CELL-ADHESION TO CULTURE PLATES AND TO TYPE-II COLLAGEN, Matrix biology, 16(9), 1998, pp. 541-561
CUPRIC NITRILOTRIACETATE INDUCES OXIDATIVE DNA-DAMAGE AND APOPTOSIS IN HUMAN LEUKEMIA HL-60 CELLS
Authors: MA YX CAO L KAWABATA T YOSHINO T YANG BB OKADA S
Citation: Yx. Ma et al., CUPRIC NITRILOTRIACETATE INDUCES OXIDATIVE DNA-DAMAGE AND APOPTOSIS IN HUMAN LEUKEMIA HL-60 CELLS, Free radical biology & medicine, 25(4-5), 1998, pp. 568-575
A PHASE-I STUDY OF SUSTAINED-DURATION FILGRASTIM IN NORMAL VOLUNTEERS
Authors: SCHWAB G ROSKOS L MOLINEUX G BRIDDELL R YANG BB CHEUNG E MILLIERMESSANA M LOCKBAUM P GARDNER S HUNT T
Citation: G. Schwab et al., A PHASE-I STUDY OF SUSTAINED-DURATION FILGRASTIM IN NORMAL VOLUNTEERS, Experimental hematology, 26(8), 1998, pp. 95-95
THE G3 DOMAIN OF VERSICAN ENHANCES CELL-PROLIFERATION VIA EPIDERMAL GROWTH FACTOR-LIKE MOTIFS
Authors: ZHANG Y CAO L YANG BL YANG BB
Citation: Y. Zhang et al., THE G3 DOMAIN OF VERSICAN ENHANCES CELL-PROLIFERATION VIA EPIDERMAL GROWTH FACTOR-LIKE MOTIFS, The Journal of biological chemistry, 273(33), 1998, pp. 21342-21351
RENAL DYSFUNCTION DOES NOT ALTER THE PHARMACOKINETICS OR LDL-CHOLESTEROL REDUCTION OF ATORVASTATIN
Authors: STERN RH YANG BB HORTON M MOORE S ABEL RB OLSON SC
Citation: Rh. Stern et al., RENAL DYSFUNCTION DOES NOT ALTER THE PHARMACOKINETICS OR LDL-CHOLESTEROL REDUCTION OF ATORVASTATIN, Journal of clinical pharmacology, 37(9), 1997, pp. 816-819
PHARMACOKINETIC AND PHARMACODYNAMIC COMPARISONS OF TWICE-DAILY AND 4 TIMES DAILY FORMULATIONS OF PROCAINAMIDE IN PATIENTS WITH FREQUENT VENTRICULAR PREMATURE DEPOLARIZATION
Authors: YANG BB ABEL RB UPRICHARD ACG SMITHERS JA FORGUE ST
Citation: Bb. Yang et al., PHARMACOKINETIC AND PHARMACODYNAMIC COMPARISONS OF TWICE-DAILY AND 4 TIMES DAILY FORMULATIONS OF PROCAINAMIDE IN PATIENTS WITH FREQUENT VENTRICULAR PREMATURE DEPOLARIZATION, Journal of clinical pharmacology, 36(7), 1996, pp. 623-633
EFFECTS OF ATORVASTATIN, AN HMG-COA REDUCTASE INHIBITOR, ON HEPATIC OXIDATIVE-METABOLISM OF ANTIPYRINE
Authors: YANG BB HOUNSLOW NJ SEDMAN AJ FORGUE ST
Citation: Bb. Yang et al., EFFECTS OF ATORVASTATIN, AN HMG-COA REDUCTASE INHIBITOR, ON HEPATIC OXIDATIVE-METABOLISM OF ANTIPYRINE, Journal of clinical pharmacology, 36(4), 1996, pp. 356-360
PHARMACOKINETICS OF A 7-DAY 17-BETA-ESTRADIOL TRANSDERMAL DELIVERY SYSTEM - EFFECT OF APPLICATION SITE AND REPEATED APPLICATIONS ON SERUM CONCENTRATIONS OF ESTRADIOL AND ESTRONE
Authors: BOYD RA YANG BB ABEL RB ELDON MA SEDMAN AJ FORGUE ST
Citation: Ra. Boyd et al., PHARMACOKINETICS OF A 7-DAY 17-BETA-ESTRADIOL TRANSDERMAL DELIVERY SYSTEM - EFFECT OF APPLICATION SITE AND REPEATED APPLICATIONS ON SERUM CONCENTRATIONS OF ESTRADIOL AND ESTRONE, Journal of clinical pharmacology, 36(11), 1996, pp. 998-1005
Risultati: 1-10 |